Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedApr 10, 2019Pantoprazole Sodium Delayed-Release TabletsDiscoloration: Expansion of an earlier recall due to the presence of dark brown discoloration on the edges of the tablets.Jubilant Cadista Pharmaceuticals, Inc. · D-1074-2019Class ITerminatedApr 10, 20198.4% Sodium Bicarbonate InjectionPresence of Particulate Matter; glass particulatesPfizer Inc. · D-1073-2019Class IIITerminatedApr 10, 2019Clindamycin InjectionFailed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time pointPfizer Inc. · D-1072-2019Class IIITerminatedApr 10, 2019Clindamycin InjectionFailed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time pointPfizer Inc. · D-1071-2019Class IIITerminatedApr 10, 2019Clindamycin InjectionFailed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time pointPfizer Inc. · D-1070-2019Class IIITerminatedApr 10, 2019Cleocin PhosphateFailed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time pointPfizer Inc. · D-1069-2019Class IIITerminatedApr 10, 2019Cleocin PhosphateFailed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time pointPfizer Inc. · D-1068-2019Class IIITerminatedApr 10, 2019Cleocin PhosphateFailed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time pointPfizer Inc. · D-1067-2019Class ITerminatedApr 3, 2019Blue Fusion CapsulesMarketed Without An Approved NDA/ANDA: FDA analysis found this product to contain undeclared ingredients: Sildenafil, Tadalafil, desmethyl carbodenafil, dithiodesmethyl...Ata International Inc · D-1085-2019Class IITerminatedApr 3, 2019Express Gel Hand SanitizerChemical Contamination: low levels of various substituted benzene (aromatic) compounds identified in the product after complaints of malodor.Ecolab Inc · D-1064-2019Class IITerminatedApr 3, 2019Quick-Care Foam Hand SanitizerChemical Contamination: low levels of various substituted benzene (aromatic) compounds identified in the product after complaints of malodor.Ecolab Inc · D-1063-2019Class IITerminatedApr 3, 2019Moisturizing Gel Hand SanitizerChemical Contamination: low levels of various substituted benzene (aromatic) compounds identified in the product after complaints of malodor.Ecolab Inc · D-1062-2019Class IITerminatedApr 3, 2019Advanced Gel Hand SanitizerChemical Contamination: low levels of various substituted benzene (aromatic) compounds identified in the product after complaints of malodor.Ecolab Inc · D-1061-2019Class IITerminatedApr 3, 2019Gel Hand SanitizerChemical Contamination: low levels of various substituted benzene (aromatic) compounds identified in the product after complaints of malodor.Ecolab Inc · D-1060-2019Class IIITerminatedApr 3, 2019Diclofenac Sodium Topical SolutionDefective Container: firm discovered samples stored horizontally as well as product quality complaints from customers for bottles leaking.Ingenus Pharmaceuticals Llc · D-1058-2019Class IITerminatedApr 3, 2019FayosimFailed Impurities/Degradation Specifications: Out-of-specification results observed in related substance test (Any Other Individual Impurity and Total impurities) in...Lupin Pharmaceuticals Inc. · D-1057-2019Class IITerminatedApr 3, 2019CombigancGMP DeviationsAllergan Sales, LLC · D-1056-2019Class IITerminatedMar 27, 2019Etomidate InjectionSubpotent Drug.Heritage Pharmaceuticals, Inc. · D-1065-2019Class IIOngoingMar 27, 2019Valsartan Tablets 320 mg USPCGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished productsRising Pharmaceuticals, Inc. · D-1055-2019Class IIOngoingMar 27, 2019Valsartan Tablets 160 mg USPCGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished productsRising Pharmaceuticals, Inc. · D-1054-2019Class IIOngoingMar 27, 2019Valsartan Tablets 80 mg USPCGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished productsRising Pharmaceuticals, Inc. · D-1053-2019Class IIOngoingMar 27, 2019Valsartan Tablets 40 mg USPCGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished productsRising Pharmaceuticals, Inc. · D-1052-2019Class IITerminatedMar 27, 2019Losartan Potassium TabletsCGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified.Preferred Pharmaceuticals, Inc · D-1051-2019Class IIOngoingMar 27, 2019Losartan Potassium TabletsCGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detectedLegacy Pharmaceutical Packaging LLC · D-1050-2019Class IIOngoingMar 27, 2019Losartan Potassium TabletsCGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detectedLegacy Pharmaceutical Packaging LLC · D-1049-2019Class IIOngoingMar 27, 2019Losartan Potassium TabletsCGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detectedLegacy Pharmaceutical Packaging LLC · D-1048-2019Class IITerminatedMar 27, 2019Valsartan Tablets USP 160 mgCGMP Deviation: Presence of NDEA (N-Nitrosodimethylamine), a carcinogen impurity, detected in the active ingredient.American Health Packaging · D-1047-2019Class IITerminatedMar 27, 2019Losartan Potassium and Hydrochlorothiazide TabletsCGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identifiedAVKARE Inc. · D-1046-2019Class IITerminatedMar 27, 2019Losartan Potassium and Hydrochlorothiazide TabletsCGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identifiedAVKARE Inc. · D-1045-2019Class IITerminatedMar 27, 2019Losartan Potassium Tablets USP 50 mg 50 TabletsCGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identifiedAVKARE Inc. · D-1044-2019Class IIOngoingMar 27, 2019Losartan Potassium Tablets USPCGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredientCamber Pharmaceuticals Inc · D-1043-2019Class IIOngoingMar 27, 2019Losartan Potassium Tablets USPCGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredientCamber Pharmaceuticals Inc · D-1042-2019Class IIOngoingMar 27, 2019Losartan Potassium Tablets USPCGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredientCamber Pharmaceuticals Inc · D-1041-2019Class IITerminatedMar 27, 2019Losartan Potassium and Hydrochlorothiazide TabletsCGMP Deviation: Presence of NDEA (N-Nitrosodimethylamine), a carcinogen impurity, detected in the active ingredient.Macleods Pharma Usa Inc · D-1040-2019Class IIOngoingMar 27, 2019Valsartan Tablets USP 160 mgGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Aurobindo Pharma USA Inc. · D-1039-2019Class IIOngoingMar 27, 2019Valsartan Tablets USP 80 mgGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Aurobindo Pharma USA Inc. · D-1038-2019Class IIOngoingMar 27, 2019Valsartan Tablets USP 40 mgGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Aurobindo Pharma USA Inc. · D-1037-2019Class IIOngoingMar 27, 2019Amlodipine and Valsartan Tablets USP 10mg/160mgGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Aurobindo Pharma USA Inc. · D-1036-2019Class IIOngoingMar 27, 2019Valsartan Tablets USP 320 mgGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Aurobindo Pharma USA Inc. · D-1035-2019Class IITerminatedMar 27, 2019Phenylephrine HClLack of Assurance of SterilityAdvanced Pharma Inc. · D-1034-2019